纵横研报
Ticker Detail

688767.SHG

¥37.08+2.52% 博拓生物 Biotechnology
00Reports China 医疗健康
Hangzhou Biotest Biotech Co Ltd
医疗健康 · 生物科技

Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, veterinary test, drug of abuse, infectious diseases, and other diagnostic rapid test. It also provides microfluidic immunofluorescence analysis system; Diagpal SE lateral flow reader, a drug tester; and Diagpal lateral flow reader, a clear image of the test is captured by a high-resolution image recognition system. In addition, the company is widely utilized across various medical institutions, judicial testing systems, third-party testing organizations, Centers for Disease Control and Prevention (CDC), and private clinics. The company was founded in 2008 and is based in Hangzhou, China.

MARKET 市值 5.55B CNY PE 177.0x 52W ¥29.84 – ¥50.04 EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG 营收 YoY 1.7% ROE 1.2% 营业利润率 -5.0% 净利润率 6.7%
ANALYST 股息率 1.89%

暂无相关研报

数据库中已收录该标的的基本面数据,可发起一份定制研报。

CUSTOM RESEARCH · 定制研报 没找到完全契合的标的?让我们替你做一份。 告诉我们你关心的标的与偏好,1 个工作日内在站内上线。 开始定制